Corticosteroid induced osteoporosis : guidelines for treatment by Sambrook, P. N. et al.
Deakin Research Online 
Deakin University’s institutional research repository 
DDeakin Research Online  
Research Online  
This is the published version (version of record) of: 
 
Sambrook, P. N., Diamond, T., Ferris, L., Fiatarone-Singh, M., Flicker, L., 
MacLennan, A., Nowson, Caryl, O'Neill, S. and Greville, H. 2001-08, 
Corticosteroid induced osteoporosis, Australian family physician, vol. 30, 
no. 8, pp. 793-796. 
 
Available from Deakin Research Online:  
 
http://hdl.handle.net/10536/DRO/DU:30008388 
 
 
Copyright to Australian Family Physician. Reproduced with 
permission. Permission to reproduce must be sought from the 
publisher, The Royal Australian College of General Practitioners. 
 
Copyright : ©2001, Australian Family Physician   
 
 
 
Copyright of Full Textrests withthe original
copyright ownerand.except as permittedunder the
CopyrightAct 1968,copying this copyrightmaterial
is prohibited without the permission of theowneror
its exclusivelicenseeoragentorby wayof a licence
from Copyright Agency Limited. Forinformation
about suchlicencescontact Copyright Agency
--Umited on (02f93947600-(ph) or (02)"93947601
(fax)
Guidelines for treatment
BACKGROUND Last year: Australian Family Plrvsician puhlished 'Guidelines for Mauagerucnt of
Postmenopausal Osteoporosis', which were developed hy Osteoporosis Australia. Recently, significant
ndvauces in our understanding of the treatment of corticosteroid osteoporosis have occurred.
OBJECTIVE The following guidelines, also developed by Osteoporosis Australia, and supported hy the
National Asthma Campaign, are to help general practitioners identify those puuents ,;\1 risk of this
problem and to provide information about current treatment strategies.
DISCUSSION Corticosteroids are widely used and effective agents for the control of many
inflammatory diseases. Corticosteroid osteoporosis is a common problem associated with the IOllg
term high dose use of these medications.
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Is there a difference
between corticosteroid and
postmenopausal
osteoporosis7
Clinically, osteoporosis is synonymous
with low bone density and predisposes to
fractures duringnormallife.
The majority of osteoporotic fractures
occur in people with bone mineral densi-
ties (BMDs) that are more than 2.5
standard deviation units below the young
normal mean (T score <-2.5). However,
bone lossdue to corticosteroids can occur
rapidly and fractures may occur at lower
reductions in T scores, so preventive
measures should be considered before
that level, especially if patients are
receiving long term corticosteroids. The
risk of fracture with corticosteroids
appears greatest in postmenopausal
women and older men. Data regarding
the risk of fracture in corticosteroid
treated premenopausal women appears
less striking. The following intervention
guidelines have been developedfrom this
data (Figure 1).
• Strongly consider preventive therapy in
patients with bonemineral density values
lower than 1.5 standard deviations below
the young normal mean (T score <-1.5)
who are starting Or receiving high doses
(more than 7.5 mg prednisone/day or
equivalent) of long term (three months
or longer) corticosteroids.
• Strongly recommend Ireatment in'
patients who are receiving long term
corticosteroids with BMD values ·lower
than 2.5 standard deviations below the
young normal mean (T score <-2.5) and
in patientswith osteoporotic fractures.
A Medicare rebate isavailable fordensitom-
etry in patients receiving greater than7.5 mg
oral prednisone (or equivalent) per day or
greater than 800 pg of inhaled beclometha-
sone or budesonide/day for more than four
months. A BMD measurement is recom-
mended in all patients starting
corticosteroids who meetthesecriteria.
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Prevention of
corticosteroid osteoporosis
Patients treatedwith corticosteroids should:
• have a diet with adequate 'calcium
content and attempt regular weight
bearingexercise where practical
• have good general nutrition with ade-
quate intake of vitamin D, especially in
elderly patients
• avoid tobacco use,
The risk of developing fractures with cor-
ticosteroid use appears to be increased by
certainfactors (Figure 1).
Although lifestyle preventjon measures
are important, pharmaceutical agents will
frequently be necessary. These agents are
discussed in more detail and are ranked
according to levels of evidence (See
Table 1, Guidelines for treatment of male
osteoporosis, page788).
Treatment of corticosteroid
osteoporosis
Calcium
Calcium is weakly antiresorptive and sup-
plementation may reduce negative
calcium balance, especially in old age.
Controlled trials': suggest calcium alone
is probably insufficient to prevent rapid
bone loss in patients starting high dose
corticosteroids (E2).
Since most controlled trials of agents,
described belnw have used concomitant
calcium and vitamin D (ergocalciferol not
calcitriol), it is appropriate to add a calcium
supplement to most therapies, except cal-
citrio!. In patients using bisphosphonates,
calcium must not be taken at the same time
of day as the bisphosphonate or the
calcium will impair absorption of the drug.
Vitamin 0 and its metabolites
Vitamin D undergoes metabolism in the
liver and kidney. Simple vitamin D is
mainly available in Australia as ergocalcif-
erol (Ostelin ]000IU per capsule), or cod
liver oil tablets (approximately 400IU).
Some calcium supplements also contain
vitamin D but in lowdose, ego Caltrate+ D
(contains 200 IU). One study in patients
with rheumatoid arthritis receiving chronic
Clinical presentation Investigation Management
". '.
'. _.. ' ' .. ~,.
-. calcitriol
. :•.. alendronate.. .
• rlsedronate i
• HRT
, Calcium supplementation.
Repeat BMD In 12 months
If corticosteroid therapy Is
ongoing .
. I":~'''''''' ..,~--:. -t." .... ...,.~~!'""-'.,?"."";~~~"'.;"- .....
, Consider preventlon.of- >'.!: ,.
, bone loss" . ;,"Si,:;'
-, ;~,
rM:;;'~ 'ris~ f~ct';;sf6r' fr~ciu~e;'
! e " Po'stmenopau·sal " . , .".
F.·Male >50y~ar~" .:".: .•. ."
! '~;. Low 'body weight,-:j. J '~~ t··::,.~J}~>!'.'",f ,.. ,o..~ . ' ...~_ • 'r 4'•• r:.. ,_
;. Low trauma fracture' .;I, ';',':, :~~:. >I - ..," .~.. :'('" -.. ,
I'· Underlyingdlseaseassoclated :'::'~r. _with ,rapid bone loss /~;.,,-,:-'.:~~'i--::I ego rheumatoid arthritis.,. ...' ',. :
;. High.dose corticosteroids' .',
," including inhaled steroids "'.: .. ' ,
I.' Low calcium intake .' . " . "
! ." Immobilisation due to underlying
condition. . ..,
!.• family history of osteoporosis
:.~e .; Ir]cre~sjng age .•
Lo.,Lowbody:weight (defined as .
, body mass index <18)
~'. lifestYle'f~~tors including
,'.- smoking, -Ia·ck of exercise
l: _..s.~_.: l_ _,_
;--.~,,- ~""":". .,.--..-;--- --_.
IA~Yfractufe'.c ~:: --"
~ ~ft,:~~~n~.maltrauma~, ::~ ..• :
Figure 1. Osteoporosis guidelines for all patients starting/receiving chronic corticosteroids.
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low dose corticosteroids for rheumatoid
arthritis' observed a small gain in bone
density in patients treated with calcium
plus500 IU/dayvitamin D3 (E2).
Calcitriol is the active hormonal form
of vitamin D. Its primary action results
from increased calcium absorption.
Several trials-'> have shown active
vitamin D metabolites (such as calcitriol)
can prevent spinal bone loss in patients
starting corticosteroids (El) although no
effect was demonstrated at the hip.
Hypercalcaemia and hypercalciuria may
occur but are uncommon in patients
treated with calcitriol in a dose of 0.5 Ilg
daily. but may occur in patients who have
a high calcium intake or who have co-
existing renal impairment. Hence calcium
supplements must be avoided in these
patients, since hypercalcaemia may
worsenthe renal failure.
Hormone replacement therapy
Long term oestrogen therapy remains the
gold standard for prevention of bone loss
in postmenopausal women but there is
little data in corticosteroid osteoporosis.
One randomised controlled trial in
patients with rheumatoid arthritis who
were receiving chronic low dose corticos-
teroids' showed a benefit of oestrogen on
bone density(E2).
In men, there has been one small trial
in asthmatic men receiving chronic corti-
costeroids comparing testosterone, 250
mg/month with calcium, 1000 mg.' After
12 months, testosterone increased lumbar
BMD by 5%, which was Significant com-
pared to calcium (E2).
Although these data do not provide
strong evidence, hormone replacement
therapy should be considered if hypogo-
nadism is present.
Selective oestrogen receptor
modulators
Selective oestrogen receptor modulators
like raloxifene act to decrease bone
resorption, like oestrogen, while not stim-
ulating the breast or uterus. One recent
controlled clinical trial suggests that
raloxifene may inhibit spinal bone loss
related to corticosteroid induced osteo-
porosis.' Raloxifene is available on the
PBS (Authority required) for established
postmenopausal osteoporosis in patients
with fracture due to minimal trauma and
could be used in women taking corticos-
teroids as an alternative to oestrogen.
Bisphosphonates
Bisphosphonates are potent inhibitors of
bone resorption. Currently three bisphos-
phonates. etidronate (Didrocal and
Didronel), alendronate (Fosamax) and
risedronate (Actonel), are approved in
Australia on the PBS (Authority
required) for the treatment of established
osteoporosis in postmenopausal women
with fracture due to minimal trauma.
Etidronate and alendronate are also
approved on the PBS (Authority
required) for the treatment of established
osteoporosis in men with fracture due to
minimal trauma.
Etidronate
This is used in a cyclical regimen for
osteoporosis, usually for two weeks
every three months. A number of con-
trolled trials with etidronate show
prevention of bone loss in patients start-
ing corticosteroids and increases in bone
density in patients on chronic corticos-
teroids.v-":" A reduction in vertebral
fracture rate wasseen inpostmenopausal
women in one study.' Etidronate has
been associated with lower, but not
upper, gastrointestinal events. The risk
of mineralisation defect with the cyclical
regimen is very low.
Alendronate
This is an aminobisphosphonate. It is a
more potent inhibitor of bone resorption
than etidronate and does not affect min-
eralisation. Several controlled clinical
trials have shown prevention of bone loss
in patients starting corticosteroids and
increases in bone density in patients on
chronic corticosteroids. A reduction in
vertebral fracture rate was seen in post-
menopausal women." The use of
alendronate may be associated with an
increased risk of upper gastrointestinal
events in patients receiving corticos-
teroids. A once weekly 70 mg
preparation may be more convenient
than 10mg daily.
Risedronate
Thisis also a more potent inhibitor of bone
resorption than etidronate, Several con-
trolled clinical trials":" have shown
prevention of bone loss in patients starting
corticosteroids and increases in bone density
in patients on chronic corticosteroids. A
reduction in vertebral fracture rate was also
seen inpostmenopausal women.
The overall evidence for bisphospho-
nates in corticosteroid osteoporosis is
such that it should be considered first line
(El ). Calcium should not be taken at the
same time of day as a bisphosphonate,
since it interferes with absorption.
Anabolic steroids
Nandrolone is frequently used in general
practice in Australia. Although long term
corticosteroid therapy is an approved indi-
cation in Australia,there is little trial data'".
to support its use in corticosteroid osteo-
porosis (E3). There is a high incidence of
virilisation withbone effective dosages and
there are no longterm safetydata.
Monitoring therapy
After corticosteroid therapy has been ini-
tiated, it is important to monitor patients
to ensure that bone loss is not excessive.
Dexa bone scan (DXA) measurements
are useful techniques for monitoring
because of their excellent precision. and
they can be performed rapidly and conve-
niently. It is worth noting that changes of
less than 3% are within the precision
error of most machines and therefore
should not be regarded as representing
significant change. Changes due to corti-
costeroidsare generally in excess of this.
Australian Family PhysicianVol. 30, No.8, August 2001 • 795
• Corticosteroid induced osteoporosis - guidelines for the treatment
It isrecommended thata repeat DXAbe
performed within a yearof starting corticos-
teroids and/or treatment to prevent
associated bone loss. Repeat measurements
should be performed on the same machine
for monitoring. It is important to remember
that patients receiving long term corticos-
teroids may have 'silent' compression
fractures, or if theyare elderly may have c0-
existing degenerative changes which may
pseudo-elevate theirspinal BMDvalues and
give a false 'sense of security'. All patients
should have spinal radiography to supple-
ment the information obtained with DXA
scans. Femoral neck BMD values may prove
to be of greater benefit in these patients.
Ultrasound should notbe used asan alterna-
tive to DXAfordiagnosis or monitoring.·
Conclusion
Postmenopausal women and older men
receiving corticosteroids are probably at
the greatest risk of rapid bone loss and
consequent vertebral fracture and should
be strongly considered for preventive mea-
sures. In younger individuals receiving
corticosteroids, the decision to use osteo-
porosis prevention is less straightforward
and will depend upon a numberof factors
including baseline BMD, anticipated dose
and duration of corticosteroids and other
risk factors. Baseduponavailable evidence
the rank order of choice for prophylaxis
would be a bisphosphonate followed by an
active vitamin D metabolite or HRT.
Although calcium alone appears unable
to prevent rapid bone loss in patients start-
ing corticosteroids, it should be considered
in those patients with normal BMDvalues.
If an active vitamin D metabolite is used,
calcium supplementation should be avoided
unless dietary calcium intake is low. The
evidence for hormone replacement is
limited, but HRT should be considered if
hypogonadism ispresent. Addition of a bis-
phosphonate in postmenopausal patients
already taking estrogen replacement
therapy may enhance the bone density
response. In patients receiving chronic low
dose corticosteroids, treatment with
calcium and vitamin D mayhelpto prevent
furtherboneloss.
Resources for patients and
healthcare professionals
Osteoporosis Australia hasa range ofeducation
materials available for patients and healthcare
professionals, which cover different aspects of
osteoporosis and its management (Free call
number 1800 242141). There areregular courses
on osteoporosis and self management, which
teach people how to maintain bone mass. how to
avoid falls and fractures, and how to live more
comfortably with osteoporosis.
Osteoporosis Australia website:
www.osteoporosis.org.au
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